Annexon ANNX 深 沪
已收盘 07-17 16:00:00 美东时间
5.80
-0.090
-1.53%
华盛通- 最 高6.155
- 今 开5.75
- 成交量 334.15万股
- 最 低 5.68
- 昨 收 5.89
- 总市值 9.50亿
- 52周最高 7.18
- 市盈率 静 --
- 换手率 2.04%
- 52周最低 2.03
- 委 比 -45.29%
- 总股本 1.64亿
- 历史最高 38.01
- 量 比 0.60
- 振 幅 8.06%
- 历史最低 1.285
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股前瞻 | 美国监管“绞杀”AI存储？闪迪、SK海力士跌逾7%，纳指期货跌近1%；谷歌逆势走强！巴菲特310亿美元重仓力挺，感叹“买晚了”
美国监管“绞杀”AI存储？闪迪、SK海力士跌逾7%，纳指期货跌近1%；谷歌逆势走强！巴菲特350亿美元重仓力挺，感叹“买晚了”！业绩超预期难抵卖压，台积电盘前跌逾4%>>
07-16 20:26
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
美股牛股 | AI数据中心需求引爆订单！AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购
Lucid劲升近29%！聘请重组顾问扭转经营颓势；AI数据中心需求引爆订单，AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购>>
07-16 19:21
美股夜盘 | AtaiBeckley Inc.涨45.52%，JB亨特运输服务涨7.91%
AtaiBeckley Inc.涨45.52%；JB亨特运输服务涨7.91%；Eos Energy Enterprises, Inc. Class A涨7.78%
07-16 13:01
Needham Maintains Buy on Annexon, Raises Price Target to $25
Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $11 to $25.
07-15 19:35
Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the Am...
07-15 04:06
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon, Inc. announced that vonaprument, a novel therapeutic for geographic atrophy (GA) in dry age-related macular degeneration (AMD), will be highlighted at the ASRS 2026 meeting. Phase 2 ARCHER trial results showed significant vision preservation, with baseline factors identified to guide Phase 3 ARCHER II patient selection. Vonaprument, a C1q inhibitor, aims to protect photoreceptor cells and retinal function. Phase 3 data are expected in Q4...
07-14 20:05
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7
Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral rating and announces Price Target of $7.
05-12 18:04
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
03-31 21:57
